Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.17 USD
Change Today -0.0125 / -6.76%
Volume 44.0K
VASO On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

vasomedical inc (VASO) Snapshot

Open
$0.17
Previous Close
$0.19
Day High
$0.19
Day Low
$0.17
52 Week High
07/9/14 - $0.32
52 Week Low
12/15/14 - $0.14
Market Cap
28.7M
Average Volume 10 Days
45.5K
EPS TTM
$0.02
Shares Outstanding
166.5M
EX-Date
--
P/E TM
11.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for VASOMEDICAL INC (VASO)

Related News

No related news articles were found.

vasomedical inc (VASO) Related Businessweek News

No Related Businessweek News Found

vasomedical inc (VASO) Details

Vasomedical, Inc. designs, manufactures, markets, and supports enhanced external counterpulsation (EECP) therapy systems, ambulatory monitoring systems, and other medical equipment to physician and hospitals in the United States and internationally. The company operates through three segments, Sales Representation, Equipment, and Information Technology (IT). Its EECP technology is a non-invasive and outpatient therapy for the treatment of cardiovascular diseases, as well as angina, cardiogenic shock, acute myocardial infarction, and congestive heart failure. The company also develops wireless multi-parameter patient monitoring systems; and distributes GE Healthcare’s diagnostic imaging products, as well as offers in-service and training support for the EECP systems. In addition, it is involved in the healthcare IT business. Vasomedical, Inc. was founded in 1987 and is headquartered in Westbury, New York.

218 Employees
Last Reported Date: 03/30/15
Founded in 1987

vasomedical inc (VASO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $275.0K
Chief Financial Officer and Secretary
Total Annual Compensation: $185.0K
Senior Vice President, Director and Chief Exe...
Total Annual Compensation: $600.0K
Vice President of Finance and Controller
Total Annual Compensation: $160.0K
Compensation as of Fiscal Year 2014.

vasomedical inc (VASO) Key Developments

Vasomedical Inc. Announces Executive Changes

On June 16, 2015, the board of directors of Vasomedical Inc. ratified the appointment of Peter C. Castle, a director of the company since August 2010, to serve as its Chief Operating Officer. Concurrently, Mr. Castle resigned as a member of the Audit and Compensation Committees since he no longer met the independence requirements of these committees. Mr. Castle was the President and Chief Operating Officer of NetWolves, LLC prior to its acquisition by the company. Mr. Castle has been employed by NetWolves since 1998 and held various positions including Controller, Treasurer and Secretary, Vice President of Finance and Chief Financial Officer. On June 16, 2015, Joshua Markowitz, Esq. was appointed by the board of directors as a director of the company to serve in Class I until the annual meeting of stockholders in 2018. He was also appointed as Chairman of the Compensation Committee of the Board. Mr. Markowitz has been a practicing attorney in the State of New Jersey for in excess of 30 years and is currently a senior partner in the New Jersey law firm of Markowitz O'Donnell, LLP.

Vasomedical, Inc. Announces Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year of Fiscal 2015

Vasomedical Inc. announced earnings results for the first quarter ended March 31, 2015. For the quarter, the company has reported that net loss was $252,000, or nil per share, compared to a net loss of $1.04 million, or $0.01 loss per share, for the same quarter ended March 31, 2014. Total revenues for the first quarter ended March 31, 2015 were $7.45 million, compared to $7.09 million for the same quarter ended March 31, 2014. Operating loss for the first quarter ended March 31, 2015 was $286,000, compared to an operating loss of $1.09 million for the same quarter ended March 31, 2014. The company generated a positive cash flow of $6.3 million from operating activities, due to improved performance in the Equipment segment and in the sales representation segment. The company provided earnings guidance for the full year of fiscal 2015. The company announced that given this momentum in first quarter, it expects to maintain annual profitability in 2015.

Vasomedical Inc., Annual General Meeting, Jun 16, 2015

Vasomedical Inc., Annual General Meeting, Jun 16, 2015., at 10:00 Eastern Daylight. Location: Homewood Suites, 40 Westbury Avenue. Agenda: To consider the election of two directors in Class I, to hold office until the 2018 annual meeting of stockholders; to consider the ratification of the appointment of Marcum LLP as independent registered public accountants for the year ending December 31, 2015; and to discuss any other matters that properly come before the meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VASO:US $0.17 USD -0.0125

VASO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hologic Inc $38.41 USD +0.28
Koninklijke Philips NV €22.98 EUR -0.23
Siemens AG €91.01 EUR +0.113
Toshiba Corp ¥423.40 JPY +5.80
View Industry Companies
 

Industry Analysis

VASO

Industry Average

Valuation VASO Industry Range
Price/Earnings 15.1x
Price/Sales 0.8x
Price/Book 3.9x
Price/Cash Flow 16.1x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VASOMEDICAL INC, please visit www.vasomedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.